

Supplementary Figures:

Figure S1. A) RNAs enriched in CD63⁺ and MHC-I⁺ EVs derived from WT Jurkat and JinB8 T cells. log2 total RPKM values show 618 transcripts present in CD63⁺ WT EVs, while 1314 in CD63⁺ JinB8 EVs respectively. Venn diagram showing overlap of 278 transcripts among total transcripts. B) log2 total RPKM values show 535 transcripts mapped in HUVEC treated with MHC-I⁺ WT Jurkat EVs while 1414 in cells treated with MHC-I⁺ JinB8 EVs, respectively. Venn diagram showing overlap of 384 transcripts among total transcripts. C&D) Types of RNAs between treatments with WT Jurkat CD63⁺ vs JinB8 CD63⁺ and WT Jurkat MHC-I⁺ vs JinB8 MHC-I⁺ based on small RNA data analysis aligned to the whole genome.

FigureS1




Figure S2. A&B) Hierarchical clustered of differentially expressed mRNA between HUVEC cells treated with WT Jurkat-derived MHC-I⁺ and JinB8-derived MHC-I⁺ EVs or CD63⁺ and JinB8-derived CD63⁺ EVs based on microarray analysis of HUVEC.




Figure S3. Validation of GSEA enrichment for EMT pathway. CD63⁺ and MHC-I⁺ EVs were extracted from WT Jurkat and JinB8 T cells and co-cultured with HUVEC for 3 days using beads as a control. mRNA expression of CTNNB1 (β -CATENIN), ZO-1, ZEB1, SLUG, SNAIL was analyzed using actin as control. A) Untreated vs Beads. B) WT Jurkat CD63⁺ vs JinB8 CD63⁺ and C) WT Jurkat MHC-I⁺ vs JinB8 MHC-I⁺.

Figure S3




Figure S4. A&B) Validation of secreted TNF α in HUVEC treated with captured MHC-I⁺ and depleted MHC-I⁻ EVs from WT Jurkat and JinB8 T cells and co-cultured with HUVEC for 24-48 h.

Figure S4

